|

ASTX030 (cedazuridine + azacitidine) Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 2/3: 1

Top Sponsors

  • Taiho Oncology, Inc.1

Indications

  • Myelodysplastic Syndrome/Neoplasm1
  • Chronic Myelomonocytic Leukemia1
  • Acute Myeloid Leukemia1
  • Myelodysplastic Syndromes1
  • Cancer1

Los Angeles, California1 trial

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

Keck School of Medicine of USC

Phase 2/3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.